Tissue Engineering and Regenerative Medicine International Society

Tissue Engineering and Regenerative Medicine International Society
Name	Tissue Engineering and Regenerative Medicine International Society
Abbreviation	TERMIS
Formation	2004
Type	International non-profit professional society
Headquarters	Lausanne
Region served	Global
Leader title	President

Contents

Tissue Engineering and Regenerative Medicine International Society

The society is an international professional association bringing together researchers, clinicians, industry leaders and policymakers focused on Regenerative medicine and Tissue engineering applications. It functions as a hub linking members from institutions such as Massachusetts Institute of Technology, Stanford University, Johns Hopkins University, University of Cambridge and Karolinska Institutet with regulatory agencies like the Food and Drug Administration, the European Medicines Agency and funding bodies including the National Institutes of Health, European Research Council, and Japan Society for the Promotion of Science. The society organizes regional chapters and global events that intersect with organizations such as International Society for Stem Cell Research, American Society for Cell Biology, European Society for Biomaterials, Biomedical Engineering Society, and industry partners like Novartis, Roche, Johnson & Johnson and Medtronic.

History

The society emerged amid rapid growth in biomaterials, cell therapy and scaffold technologies following landmark developments at Harvard University, University of California, Berkeley, University of Pennsylvania, Imperial College London and ETH Zurich. Founding meetings involved representatives from United Kingdom, United States, Japan and Australia alongside leaders from institutions such as Mayo Clinic, Cleveland Clinic, Karolinska Institutet and Monash University. Early collaborations linked with initiatives funded by the Wellcome Trust, the Howard Hughes Medical Institute and the European Commission Framework programmes. The society’s regionalization mirrored models used by World Health Organization partnerships and mirrored organizational evolutions seen in associations like American Association for the Advancement of Science and Royal Society.

The society’s declared mission parallels goals advanced by United Nations science initiatives: to accelerate translation from bench to bedside, to promote standards in Good Manufacturing Practice adoption, and to foster interdisciplinary training across universities such as UCL, Johns Hopkins University School of Medicine and Seoul National University. Objectives include convening stakeholders from European Medicines Agency and Food and Drug Administration for regulatory dialogue, supporting translational pipelines akin to programs at National Institutes of Health and Canadian Institutes of Health Research, and endorsing ethical frameworks comparable to guidance from International Society for Stem Cell Research and Council for International Organizations of Medical Sciences.

Governance features an elected board and regional chapters reflecting models used by International Committee of the Red Cross and International Council for Science. Membership comprises academic investigators from labs at MIT Koch Institute, clinicians from Mayo Clinic, industry scientists from firms such as Pfizer and AstraZeneca, and representatives of standards bodies like International Organization for Standardization and European Committee for Standardization. Committees address education, standards, regulatory affairs and ethics, coordinating with universities like University of Toronto, The University of Melbourne and Peking University. Membership tiers mirror professional societies such as American Association of Immunologists and Society for Neuroscience.

The society convenes triennial and regional congresses modeled after major scientific meetings like the American Society of Clinical Oncology annual meeting and the American Chemical Society national meetings. Major congresses rotate among host cities such as Boston, London, Tokyo, Sydney and Zurich and attract keynote speakers from institutions like Harvard Medical School, University of Oxford and Stanford School of Medicine. Sessions often include regulatory panels featuring officials from Food and Drug Administration and European Medicines Agency, translational symposia patterned on NIH workshops, and industry exhibitions with companies such as GE Healthcare and Siemens Healthineers.

The society endorses and contributes to guidance documents and consensus statements similar to those published by International Society for Stem Cell Research and World Health Organization. It supports journals and special issues involving editorial boards from Nature Biotechnology, Science Translational Medicine, Biomaterials and Tissue Engineering and collaborates with publishers associated with Elsevier, Springer Nature and Wiley. Working groups produce position papers on manufacturing standards, preclinical models and clinical trial design that are cited alongside documents from the European Medicines Agency and Food and Drug Administration.

Annual and biennial awards honor contributions in basic science, translational research and clinical innovation, modeled after prizes from Lasker Foundation, Royal Society medals and Gairdner Foundation recognition. Past awardees have included investigators affiliated with Johns Hopkins University, MIT, University of California, San Francisco, Imperial College London and ETH Zurich. Industry innovation awards parallel recognition programs at Pharmaceutical Research and Manufacturers of America and collaborations with foundations such as Bill & Melinda Gates Foundation for global health impact.

The society collaborates with regulatory and standard-setting organizations including Food and Drug Administration, European Medicines Agency, International Organization for Standardization and national agencies like Health Canada and Therapeutic Goods Administration. It engages with consortia and funding agencies such as Horizon Europe, National Institutes of Health and European Research Council to influence translational funding priorities, clinical trial frameworks and manufacturing guidelines. Policy engagement has touched intellectual property discussions involving World Intellectual Property Organization and reimbursement debates appearing before bodies like Centers for Medicare & Medicaid Services and national health technology assessment agencies such as National Institute for Health and Care Excellence.

Category:Scientific societies